ForPatients
by Roche

Breast Cancer HER-2 Positive Breast Cancer HER2-Positive Breast Cancer

A study to investigate the effectiveness of trastuzumab emtansine compared with trastuzumab in a type of breast cancer (called HER2 positive breast cancer) for patients who still have signs of tumours after receiving previous treatment and undergoing surgery (KATHERINE)

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Trial Status	Trial Runs In	Trial Identifier
Completed	28 Countries	NCT01772472 2012-002018-37 BO27938

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy. Eligible patients will be randomized to receive either trastuzumab emtansine 3.6 mg/kg or trastuzumab 6 mg/kg intravenously every 3 weeks for 14 cycles. Radiotherapy and/or hormone therapy will be given in addition if indicated.

Hoffmann-La Roche Sponsor	**Phase 3** Phase

NCT01772472 2012-002018-37 BO27938
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=18 Years	No

© 2022 F. Hoffmann-La Roche Ltd